益气活血解毒方联合化疗治疗晚期卵巢癌疗效及对患者免疫通路相关靶基因的影响  

The effect of Yiqi Huoxie Jiedu decoction combined with TC regimen on advanced ovarian cancer and related target genes of immune pathway

作　　者：李成斐 朱萍 于佳 刘俊彦 刘叶玲[3] LI Chengfei;ZHU Ping;YU Jia;LIU Junyan;LIU Yeling(Chinese People’s Liberation Army Naval Hospital 971,Qingdao 266000,China)

机构地区：[1]海军第九七一医院,山东青岛266000 [2]山东第一医科大学附属肿瘤医院,山东济南250000 [3]泰安市中心医院,山东泰安271000

出　　处：《陕西中医》2021年第8期1072-1075,1079,共5页Shaanxi Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(30471806)。

摘　　要：目的:探讨益气活血解毒方联合TC方案(紫杉醇联合卡铂)对晚期卵巢癌气虚血瘀证疗效及对患者免疫通路相关靶基因的影响。方法:选择108例晚期卵巢癌气虚血瘀证患者为研究对象,以随机数字表法分为对照组(采用TC方案化疗)和观察组(在对照组的基础上联合益气活血解毒方治疗),每组均为54例,两组均治疗两个疗程。比较两组治疗前后中医症状评分、T淋巴细胞亚群细胞水平,比较两组治疗后临床控制率以及免疫通路相关靶基因表达水平,统计两组治疗期间不良反应发生情况。结果:治疗前,两组中医症状评分、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、丝裂原活化蛋白激酶3(MAPK3)、CD40、杀伤细胞免疫球蛋白样受体2DL3(KIR2DL3)、人类淋巴细胞抗原DQA(HLA-DQA)比较,差异无统计学意义(P>0.05);治疗后,两组中医症状评分、MAPK3、CD40、KIR2DL3、HLA-DQA均比治疗前低(P<0.05),且观察组低于对照组(P<0.05);治疗后,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)均比治疗前高(P<0.05),且观察组更高(P<0.05);治疗后,观察组临床控制率比对照组高(83.33%与64.81%,P<0.05);两组治疗期间贫血、恶心呕吐、脱发、白细胞降低等Ⅲ和Ⅳ级不良反应发生率相近(P>0.05)。结论:益气活血解毒方联合TC方案用于治疗晚期卵巢癌气虚血瘀证患者,能够改善患者的临床症状,疗效显著,调节机体免疫功能水平及相关免疫通路。Objective:To explore the effect of Yiqi Huoxie Jiedu decoction combined with TC regimen(paclitaxel combined with carboplatin)on advanced ovarian cancer with Qi deficiency and blood stasis syndrome and its influence on immune pathway-related target genes.Methods:A total of 108 patients with advanced ovarian cancer with Qi deficiency and blood stasis syndrome were selected as the research objects.They were divided into a control group(with TC regimen chemotherapy)and an observation group(on the basis of the control group,combined with Yiqi Huoxie Jiedu decoction)by random number table,and there were 54 cases in each group,and both groups were treated for two courses.The Chinese medicine symptom scores and T lymphocyte subgroup cell levels of the two groups before and after treatmentwere compared,and compared the clinical control rate and the expression levels of immune pathway-related target genes after the two groups,and count the occurrence of adverse reactions during the treatment of the two groups.Results:Before treatment,the two groups of Chinese medicine symptom scores,leukocyte differentiation antigen 4^(+)(CD4^(+)),CD8^(+),CD4^(+)/CD8^(+),mitogen-activated protein kinase 3(MAPK3),CD40,killer cell immunoglobulin-like receptor 2DL3(KIR2DL3),human lymphocyte antigen DQA(HLA-DQA)were compared,the difference was not statistically significant(P>0.05),after treatment,the two groups of Chinese medicine symptom scores,MAPK3,CD40,KIR2DL3,HLA-DQA were lower than before treatment(P<0.05),and the observation group is lower than the control group(P<0.05).After treatment,the two groups of CD4^(+),CD8^(+),CD4^(+)/CD8^(+)were higher than before treatment(P<0.05),and the observation group was higher(P<0.05),after treatment,the clinical control rate of the observation group was higher than that of the control group(83.33%vs.64.81%,P<0.05).The incidence of gradeⅢandⅣadverse reactions such as anemia,nausea and vomiting,alopecia,and leukopenia were similar in the two groups during treatment(P>0.05).Conclusion:Yiqi Huoxue Jie

关 键 词：卵巢癌 晚期 益气活血解毒方 免疫功能 免疫通路相关靶基因 

分 类 号：R737.31[医药卫生—肿瘤]